Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2025)
Historic Common Equity for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$861000.0.
- Xeris Biopharma Holdings' Common Equity rose 9696.01% to -$861000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$861000.0, marking a year-over-year increase of 9696.01%. This contributed to the annual value of -$29.6 million for FY2024, which is 33667.06% down from last year.
- Latest data reveals that Xeris Biopharma Holdings reported Common Equity of -$861000.0 as of Q3 2025, which was up 9696.01% from -$19.3 million recorded in Q2 2025.
- Xeris Biopharma Holdings' 5-year Common Equity high stood at $96.5 million for Q1 2022, and its period low was -$35.1 million during Q1 2025.
- Over the past 5 years, Xeris Biopharma Holdings' median Common Equity value was -$861000.0 (recorded in 2025), while the average stood at $15.4 million.
- As far as peak fluctuations go, Xeris Biopharma Holdings' Common Equity skyrocketed by 233648.92% in 2022, and later crashed by 83280.72% in 2024.
- Over the past 5 years, Xeris Biopharma Holdings' Common Equity (Quarter) stood at $95.2 million in 2021, then plummeted by 52.55% to $45.2 million in 2022, then tumbled by 115.01% to -$6.8 million in 2023, then tumbled by 336.67% to -$29.6 million in 2024, then soared by 97.09% to -$861000.0 in 2025.
- Its Common Equity was -$861000.0 in Q3 2025, compared to -$19.3 million in Q2 2025 and -$35.1 million in Q1 2025.